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Abstract
Background: Long non-coding RNAs (lncRNAs) have emerged as key players in a remarkably variety of biological
processes and pathologic conditions, including cancer. Next-generation sequencing technologies and bioinformatics
procedures predict the existence of tens of thousands of lncRNAs, from which we know the functions of only a
handful of them, and very little is known in cancer types such as head and neck squamous cell carcinomas (HNSCCs).
Results: Here, we use RNAseq expression data from The Cancer Genome Atlas (TCGA) and various statistic and
software tools in order to get insight about the lncRNome in HNSCC. Based on lncRNA expression across 426 samples,
we discover five distinct tumor clusters that we compare with reported clusters based on various genomic/genetic
features. Results demonstrate significant associations between lncRNA-based clustering and DNA methylation, TP53
mutation, and human papillomavirus infection. Using “guilt-by-association” procedures, we infer the possible biological
functions of representative lncRNAs of each cluster. Furthermore, we found that lncRNA clustering is correlated with
some important clinical and pathologic features, including patient survival after treatment, tumor grade, or sub-
anatomical location.
Conclusions: We present a landscape of lncRNAs in HNSCC and provide associations with important genotypic and
phenotypic features that may help to understand the disease.
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Background
Head and neck cancer is the sixth leading cancer world-
wide, with an estimated 600,000 new cases annually and
a 50% 5-year mortality rate (Globocan 2012) [1]. As
more than 90% of this cancer cases are of squamous ori-
gin, they are generally referred to as head and neck
squamous cell carcinoma (HNSCC). HNSCC arises in
the upper aerodigestive tract, comprising the nasal cavity
and paranasal sinuses, oral cavity, pharynx, larynx, and
trachea. The main risk factors associated with its devel-
opment are tobacco and alcohol consumption, which
have a synergistic effect when combined, and also hu-
man papillomavirus (HPV) infection [2, 3]. HPV is
known to drive tumorigenesis through the actions of its
major oncoproteins E6 and E7, which can inactivate p53
and retinoblastoma (Rb) tumor supressors, respectively,
altering cell cycle regulation in infected cells. HPV-
positive differ from HPV-negative HNSCCs in tumor
biology and clinical characteristics, including clinical
outcomes, since HPV-positive tumors have been associ-
ated with a more favorable prognosis [4]. HNSCC pa-
tients are frequently treated with surgery, together with
radiotherapy and/or cisplatin-based chemotherapy. Pa-
tients with aggressive disease are treated with cetuximab,
an anti-EGFR antibody. Few patients respond to this
therapy, and there is no molecular stratification of the
patients nor biomarkers of responsiveness [2]. Previous
characterization of molecular features in HNSCC, par-
ticularly with the aid of large-scale cancer genomics ini-
tiatives such as The Cancer Genome Atlas (TCGA), has
generated important insights for stratifying patients and
delineating tumor subtypes [5–7]. These multiomic
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analyses do not take into account the vast long non-
coding transcriptome that may substantially contribute
to HNSCC pathogenesis and progression.
LncRNAs are transcripts longer than 200 nucleotides
that have no apparent protein coding potential [8]. They
are highly diverse and actively present in many aspects
of cell biology, including cellular differentiation, prolifer-
ation, DNA damage response, dosage compensation, and
chromosomal imprinting. LncRNAs are categorized as
exonic, intronic, intergenic, antisense, or overlapping
based on their genomic location relative to a protein
coding gene. The most recent estimate of the
Encyclopedia of DNA Elements (ENCODE) Project
Consortium (GENCODE version 25) is that the human
genome contains more than 15,000 lncRNA genes that
encode almost 28,000 transcripts [9] although the total
number is estimated to be much higher. Like the protein
coding genes (PCGs), lncRNA genes are regulated tran-
scriptionally and by histone modification, and lncRNA
transcripts are processed by the canonical splicing ma-
chinery [10]. In addition, lncRNAs have fewer exons
than PCGs, are usually located in the nucleus, are sub-
ject to less selective pressure during evolution, and show
higher tissue or cell type specificity. Given the large
number of lncRNAs that are predicted to exist, it is ex-
pected that the functions in which they are involved may
include many of the known (and possibly new) biological
and physiological processes. Some of the molecular
functions described so far include chromatin interac-
tions, transcriptional regulation, RNA processing, mRNA
stability or translation, or signaling cascade modulation
[11]. In the context of cancer phenotypes, lncRNA func-
tions have been found in proliferation, growth suppres-
sion, motility, immortality, angiogenesis, and viability
[11, 12]. Unfortunately, the possible functions or pheno-
typic effect of the vast majority of lncRNAs remains elu-
sive in normal homeostasis or in cancer [12, 13], and is
difficult to analyze [14].
Comprehensive genomic analysis across human can-
cers demonstrated that a large number of lncRNAs show
differential expression among known tumor subtypes
[15–17]. In addition, lncRNA alterations are highly
tumor and lineage specific [15–17]. The expression of
known, tumor-associated lncRNAs, such as HOTAIR,
NEAT1, UCA1, MALAT1, and MEG3, has been tested
in HNSCC and correlated with clinicopathologic param-
eters [18]. Functional studies have tested the effects in
proliferation, apoptosis, invasion, and migration in
HNSCC cell lines after RNA interference (RNAi) of spe-
cific lncRNAs [19]. In addition, lncRNA profiling has
been done in HNSCC, assessing deregulation between
normal and tumor samples, associations with clinical pa-
rameters, HPV infection or mutation in the TP53 tumor
suppressor gene [19–21].
To our knowledge, no comprehensive reports studying
the clusterization of human primary HNSCC samples
based on genome-wide lncRNA expression have been
published. Therefore, the main objective of this report is
to analyze the long non-coding transcriptome in
HNSCC in order to discover new tumor clusters. Fur-
thermore, we investigate whether lncRNA-based cluster-
ization is useful to predict patient’s clinical outcome, and
is associated with important clinicopathologic parame-
ters. Finally, we interrogate the dataset to infer the pos-
sible biological functions of lncRNAs in HNSCC based
on correlation patterns of the PCGs.
Methods
Data resources
Expression values of 12,727 lncRNA genes from 426
HNSCC primary tumor samples of the TCGA RNAseq
cohort were downloaded from the TANRIC web page
[22]. Methods used to extract these expression values
have been described [16]. Briefly, the genomic coordi-
nates of the human lncRNAs from the GENCODE
Resource (version 19) were obtained. Thereafter, the
lncRNA exons that overlapped with any known coding
genes based on the gene annotations of GENCODE and
RefGene were filtered out. As a result, the analysis fo-
cused on the remaining 12,727 lncRNAs. Based on the
BAM files, the expression levels were quantified as
RPKM, and the lncRNAs with detectable expression
were defined as those with an average RPKM ≥0.3 across
all samples in each cancer type, as defined in the litera-
ture. The Ensembl identifiers of the 500 lncRNA genes
displaying the highest variability in HNSCC were kindly
provided by Dr. H. Liang at the Research Group from
the Department of Bioinformatics and Computational
Biology of The University of Texas and the MD Anderson
Cancer Center. We downloaded DNA methylation, CNV,
miRNA, and reverse phase protein array (RPPA) cluster-
ing data, as well as HPV infection and PCG mutations for
the TCGA HNSCC dataset using the cBioPortal [23], the
UCSC Xena [24] and the TCGA [25] repositories.
Unsupervised clustering analysis
Consensus Cluster Plus (CCP) tool [26], which is imple-
mented as an R language package from Bioconductor
[27], extends the CC algorithm and is briefly described
here. The algorithm begins by subsampling a proportion
of items and a proportion of features from a data matrix.
Each subsample is then partitioned into up to k groups
by a user-specified clustering algorithm. This process is
repeated for a specified number of times. Pairwise con-
sensus values, defined as “the proportion of clustering
runs in which two items are grouped together,” are
calculated and stored in a consensus matrix (CM) for
each k. Clustering settings used were as follows:
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maxK = 6; number of bootstraps = 1000; item subsampling
proportion = 0.8; feature subsampling proportion = 1; clus-
ter algorithm = pam; inner linkage type = complete; final
linkage type = complete; correlation method = Euclidean.
Consensus CDF plot and proportion of ambiguous clus-
tering (PAC) per each k was obtained.
Analysis of tumor clusters revealed by lncRNA expression
The association between lncRNA-based sample clusters
and sample clusters based on other molecular features/
aberrations was done using Fisher’s exact test for four-
fold (2 × 2) tables or chi-square test for more than four-
fold comparisons. Both tests are used to determine
whether there are significant differences between the ex-
pected frequencies and the observed frequencies in one
or more categories. Kaplan-Meier curves were obtained
using the follow-up time of the HNSCC patients of two
end-points: recurrence and death. Statistical analyses
were done with SPSS 14.0.
Guilt-by-association (GBA) analysis
Pearson correlation analysis was used to select lncRNA
genes with significant correlation between artificial ex-
pression vectors or templates (t1 to t5) (Fig. 2a), or be-
tween mean expression values of correlated lncRNAs
and PCGs. We select both direct and inverse correlation
patterns by setting thresholds either at the Pearson (r)
value or at the associated p val. Pearson’s r values range
between −1 and +1, such that two perfectly correlated
genes display r = 1, and two perfectly anticorrelated
genes r = −1. lncRNA surrogate selection was done setting
r > 0.3 with respect to the corresponding template (associ-
ated p val <1 × 10−6). Additional filtering criteria include
average RPKM ≥0.1 within specific clusters, and overex-
pression between normal tissue and specific clusters (T
test, corrected p val <0.05). PCGs directly or inversely
correlated with lncRNAs were selected using r > 0.3,
or r < −0.3 with respect to mean expression values of se-
lected lncRNAs per cluster, respectively (associated p val
<1 × 10−9). Correlations as well as heatmap drawings were
performed using MultiExperiment Viewer v4.9 (MeV) [28].
Gene ontology analysis
Selected PCGs were analyzed with the Gene Functional
Annotation Tool available at the DAVID v6.7 website
[29, 30] using their official gene symbols. Gene ontology
option GOTERM_BP_FAT was selected and a functional
annotation chart generated. A maximum p value of 0.05
was chosen to select only significant categories.
Results
HNSCC sample clusters based on lncRNA expression
In order to discover HNSCC tumor subgroups, we se-
lected the 500 lncRNAs (Additional file 1: Table S1) with
the most variable expression pattern in HNSCC [16] and
the Consensus Cluster Plus (CCP) software tool (see
“Methods”). CCP analysis revealed the presence of five
HNSCC clusters, which we have named clusters 1 to 5
(Fig. 1 and Additional file 1: Table S2). The results sug-
gest that lncRNAs can distinguish five HNSCC subtypes,
having significant differences in lncRNA expression.
LncRNA clustering resembles DNA methylation and mRNA
clustering
In order to assess the correlation between lncRNAs and
additional molecular features, we analyze whether
lncRNA clustering resembles previously described sam-
ple clustering based on mRNA, miRNA, protein (RPPA)
expression, DNA methylation, and CNV. For this, we
downloaded clustering data from the TCGA HNSCC
dataset [5] and compared them with lncRNA subgroups
using contingency analyses (Chi-square test, see
“Methods”). The results showed highly significant
similarities between our clusterization and DNA methy-
lation clusters (p val = 4.6 × 10−34) or mRNA-based sub-
types (p val = 4.2 × 10−30) (Fig. 2a). LncRNA clustering
displays lower overlapping with CNV, miRNA, and
RPPA subtypes, with p values ranging from 2.8 × 10−15
to 3.5 × 10−5 (Fig. 2a). The high overlapping between
lncRNA and mRNA subgroups is suggestive of similar
molecular mechanisms of expression control. Also, the
contingency results suggest that lncRNA expression
might be strongly influenced by DNA methylation (or
vice versa), an important mechanism of epigenetic tran-
scriptional regulation.
HPV-infected tumors display a specific lncRNAome
A significant proportion of tumor samples from the re-
ported TCGA dataset [5] having 279 samples, is infected
with HPV (almost 13%). Interestingly, a deep, multiplat-
form analysis of the molecular features of HNSCC pri-
mary tumors from the TCGA, demonstrated strong
differences between HPV-positive and HPV-negative
samples [5]. Infected cancers display different mutational
landscape, mainly characterized by the absence of TP53
gene mutations. Chi-square test demonstrated that
lncRNA clustering is highly significantly associated with
HPV (p val = 1.5 × 10−29) (Fig. 2b), indicating infected tu-
mors display a specific lncRNA landscape. Interestingly,
a deeper analysis shows that almost all samples from
cluster 5 (c5) are HPV positive (24 out of 29) (p val =
4.0 × 10−21) (Fig. 2d). Similar results were reported in the
TANRIC study [16].
HNSCC mutations and lncRNA clustering
In order to discover whether particular lncRNA clusters
are characterized by the presence or absence of HNSCC
mutations, we interrogate lncRNA cluster and mutation
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associations using Chi-square test (Fig. 2b–d). We se-
lected a total number of 19 genes, found to be signifi-
cantly mutated in the TCGA HNSCC cohort: CDKN2A,
FAT1, TP53, CASP8, AJUBA, PIK3CA, NOTCH1,
KMT2D, NSD1, HLA-A, TGFBR2, HRAS, FBXW7, RB1,
PIK3R1, TRAF3, NFE2L2, CUL3, and PTEN. Significant
associations between these mutations and lncRNA-based
clustering are shown (Fig. 2c). Cluster 1 (c1) is enriched
in TP53 and NSD1 mutations, cluster 2 (c2) display fre-
quent TP53 and KMT2D mutations, and cluster 4 (c4)
frequent CASP8, NOTCH1, and CDKN2A mutations. In
addition, cluster c5 is depleted of TP53 and CDKN2A
mutations, as most samples are HPV-infected. Finally,
cluster 4 (c4) is depleted of KMT2D mutations. Both
A B C
Fig. 1 Unsupervised clustering of HNSCC using lncRNA expression data. a Consensus Cluster Plus analysis identifies five major groups (samples,
n = 426). The blue and white heatmap displays sample consensus. Number of samples per cluster is shown. Consensus CDF plot (b) and PAC
values (c) for k = 2 to 6 are represented. Smaller PAC values are obtained with k = 5 and k = 6, with minor differences between them. Therefore,
k = 5 was selected. Specifications and parameters used in the analysis are described in the “Methods” section
A B
C D
Fig. 2 lncRNA clusters and other molecular aberrations. a LncRNA-based clustering of HNSCC samples is significantly associated with clustering
based on diverse molecular features, mainly DNA methylation and expression of PCGs (mRNA). Significance values are plot upon chi-square test
computation. b, c Association with HPV infection and HNSCC mutations with lncRNA clusters. Chi-square or odds ratio values are plot upon
chi-square test (b) or Fisher’s exact test (c) computation, respectively. Dashed red line: threshold of significance (p val <0.05). d Distribution of
lncRNA clusters and HPV-infected samples or samples with mutations in KMT2D or NSD1. Note the enrichment of HPV infection in c5, the NSD1
mutations in c1, and the KMT2D mutations in c2 (red lines) and the depletion of KMT2D mutations in c4 (green line). p values are calculated with
Fisher’s exact test. Vertical black lines in d showed HPV+ samples and mutated samples for the selected genes KMT2D and NSD1, respectively
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KMT2D and NSD1 are methyltransferases involved in
methylation of H3K4 and H3K36, respectively, which are
important epigenetic regulators of gene expression. Most
mutations found for both proteins are truncating, there-
fore indicating that c1 and c2 are characterized by loss-
of-function of histone modifiers.
Guilt-by-association (GBA) analysis: selection of surrogate
lncRNAs per cluster
In order to select candidate lncRNAs for further ana-
lysis, we decided to perform differential expression ana-
lysis using the clustering information. Our aim was to
select lncRNAs surrogate of each of the five clusters, so
they are overexpressed only in one cluster. We designed
five expression vectors or templates, (t1 to t5, see Fig. 3a)
from which we performed Pearson correlation analysis
(see “Methods”) onto the lncRNA genes from which ex-
pression values are available for HNSCC (n = 12,727).
The output are lncRNAs whose expression patterns are
(i) expressed in the specific cluster, (ii) overexpressed in
the specific cluster versus normal tissue, and (iii) sig-
nificantly correlated with the corresponding template
(r > 0.3 and p val <10−6). The number of selected
lncRNAs per cluster and the heatmap showing ex-
pression patterns is shown (Fig. 3b and Additional file 1:
Table S3): c1 = 91, c2 = 275, c3 = 9, c4 = 13, and c5 = 245.
Note that clusters c2 and c5 display the highest numbers
of lncRNA genes, and c3 and c4 the lowest. Interestingly,
16 out of 245 lncRNAs in cluster c5, depleted in TP53
mutations (Fig. 2c, d), have been shown to be overex-
pressed in TP53 wild type HNSCC samples [20]. In
addition, 12 out of 245 c5 lncRNA genes were found up-
regulated in HPV-infected samples [20], in line with high
frequency of HPV-positive samples in this cluster (Fig. 2d
and Additional file 1: Table S5).
Associated PCGs to surrogate lncRNAs
Predicting the biological functions of lncRNAs is chal-
lenging. GBA analysis has been proposed on the basis
that the function of a poorly characterized lncRNA gene
can be inferred from known/predicted functions of pro-
tein coding genes which are coexpressed [31]. We lever-
aged our RNA-sequencing data using GBA analysis to
generate hypotheses on functional significance by com-
paring the expression of lncRNAs to protein coding
genes of known function. Therefore, we performed cor-
relation analysis to interrogate what coding genes are
directly or inversely correlated with the surrogate
lncRNA genes of each cluster. Accordingly, we use five
different expression vectors or templates, one per clus-
ter, calculated from the mean expression value of
lncRNAs selected per cluster above (Fig. 3b). The num-
ber of correlated genes per cluster and the heatmap
showing their expression patterns are shown (Fig. 3c, d)
for directly (overexpressed PCGs) or inversely (under-
expressed PCGs) correlated PCGs. Thresholds used
are r > 0.3 or r < −0.3 and p val <1 × 10−9 (Additional
file 1: Table S4).
The results shown that each lncRNA cluster has asso-
ciated a significant number of coding genes, whose func-
tions might be related with the biological roles of the
correlated lncRNAs.
Gene ontology analysis of lncRNA clustering-associated
PCGs
In order to predict possible functions of the surrogate
lncRNAs in each cluster, we perform enrichment ana-
lysis of GO Biological Processes (GOBP) on the associ-
ated PCGs, which would find enriched pathways and
A B
C D
Fig. 3 Guilt-by-association (GBA) analysis. a Schema graph showing
approach used to search for lncRNA genes as surrogates of each
cluster. Briefly, Pearson correlation was computed between all
lncRNAs and artificial expression vectors or templates (templates t1
to t5) whereby maximum expression in individual clusters with
respect to the others was interrogated. Threshold used: r > 0.3 and
p val <1 × 10−6. Additional filtering criteria include average RPKM
≥0.1 within specific clusters and overexpression between normal
tissue and specific clusters (T test, corrected p val <0.05). b Heatmap
exhibiting selected lncRNAs upon Pearson correlation and the
corresponding gene numbers per cluster. Heatmaps of PCGs directly
(overexpressed PCGs) (c) or inversely (underexpressed PCGs) (d)
correlated with the lncRNAs selected per cluster in b. Threshold
used: r > 0.3 and p val <1 × 10−9 for overexpressed PCGs; r < −0.3
and p val <1 × 10−9 for underexpressed PCGs
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larger processes made up of the activities of the PGC
gene products. Therefore, we analyze individually the
lists of PCGs directly or inversely correlated with each
lncRNA cluster (Fig. 4). Cluster c1 is characterized by
the underexpression of PCGs involved in T cell, natural
killer cell, and myeloid leukocyte activation; these pro-
cesses are overexpressed in c5, suggesting important dif-
ferences in immune response between c1 and c5.
Importantly, PD-L1 (CD274), an immune inhibitory re-
ceptor ligand whose inactivation using antibodies is be-
ing currently used for cancer treatment successfully, is
underexpressed in c1. Cluster c2 is characterized by the
expression of positive regulators of transcription, tissue
morphogenesis, and neuronal markers. In addition, c2
exhibits depletion of PCGs involved in ubiquitin-
dependent protein cleavage, including some protein
component of the proteasome complex (PSM proteins).
Cluster c3 express coding genes involved in cell migra-
tion, and underexpress PCGs involved in glucose metab-
olism. Cluster c4 contain overexpressed PCGs involved
in epidermal development, including late cornified enve-
lope (LCE) cluster genes and small proline-rich protein
(SPRR) genes. Both LCE and SPRR proteins are
expressed in terminally differentiated stratified epithelia,
such as skin or head and neck mucosa. Underexpressed
coding genes in c4 are involved in protein translation,
similar to those in c5. Cluster c5 has many overex-
pressed PCGs involved in DNA replication and cell cycle
processes, RNA splicing or transcription. Overall, the re-
sults highlight important differences between lncRNA
clusters in terms of predicted functions, somehow
validating the unsupervised clustering and Pearson cor-
relation analysis performed. Whether the surrogate
lncRNAs of each cluster are also involved in these bio-
logical functions remains to be demonstrated.
Clinical and pathological features in lncRNA groups
We wanted to investigate whether our lncRNA clusters
could display different clinical and pathological charac-
teristics, possibly providing a better understanding of the
patient’s tumor behavior or response to current therap-
ies. We analyze whether patient sample clusters display
follow-up differences in recurrence or in death, after
treatment. Therefore, we performed Kaplan-Meier sur-
vival plots for both end-points (recurrence or overall
survival) and the five clusters. Results show significant
differences in overall survival at 5 years (p val = 0.0065,
log-rank test) as previously described [16], with c5 pa-
tients having the highest probabilities of survival (Fig. 5a).
In addition, patients within c1 and c2 clusters exhibit
the lowest survival. No significant statistical differences
were found, however, in recurrence after treatment
(Additional file 2: Figure S1).
Also, we examined tobacco smoking history and
found more smokers in c1 and c2 than expected by
chance (p val = 0.02 and 0.0002, respectively, upon Fisher’s
test) (Fig. 5b). No differences were found in alcohol con-
sumption between patient clusters. Interestingly, we show
that tumor histology grade (G1, G2, G3, or G4) is associ-
ated with lncRNA clustering (p val = 6.58 × 10−10, Chi-
square test). More specifically, we found that c5 tumors
have frequently poorly differentiated and undifferentiated
Fig. 4 GOBP terms selected by cluster. Gene ontology analysis was done using DAVID v6.7 web tool (see the “Methods” section). Overexpressed
or underexpressed PCGs are analyzed per cluster, and representative GO Biological Processes (GOBP) terms shown. Numbers at the end of each
bar represent genes belonging to each GOBP term. Dashed red line denotes threshold for significant enrichment (p val <0.05)
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histology (G3 and G4, respectively) compared with the
other clusters, while c4 have more differentiated or mod-
erately differentiated tumors (G1 or G2, respectively). Fur-
thermore, sub-anatomic location of the tumors and
cluster subdivision were significantly associated (p val =
5.1 × 10−41, Chi-square test), so that c1 and c2 tumors are
frequently found in the larynx, c4 in the tongue, and c5 in
the tonsil (Fig. 5b). Interestingly, 4 lncRNA genes from c1
and 10 from c2 have been shown to be overexpressed in
the larynx (Additional file 1: Table S6) [20]. Finally, we
found that c1 patients are younger than the remaining pa-
tients (58.2 versus 61.6 years, p val = 0.018 after T test),
and c2 patients older (65 versus 60.2 years, p val = 0.001
after T test) (Fig. 5c).
In summary, lncRNA clusterization is associated with
important molecular aberrations and clinicopathologic
features, providing important genomic and phenotypic
relationships. Table 1 summarizes the main associated
features of each lncRNA cluster.
Discussion
The recent implication of lncRNAs in many biological
functions has established a new scenario to better under-
stand complex processes like cancer [12, 13]. Traditional
genomic characterizations have produced minimal im-
provements in patient clinical outcome, with a mortality
rate of 50%. Therefore, lncRNAs may represent a prom-
ising field to discover novel diagnostic and therapeutic
strategies. Here we analyzed the lncRNA expression pat-
terns of HNSCC from 426 TCGA primary tumor sam-
ples to generate insights into the landscape of lncRNAs
in HNSCC.
Interestingly, we discover five clusters of samples
based on lncRNA expression with significant differences
in molecular aberrations and clinicopathologic features.
lncRNA clustering resembles clustering based on DNA
methylation and mRNA features. DNA methylation is a
chemical modification of genomic DNA by the addition
of a methyl group (–CH3) to the cytosine or adenine
DNA nucleotides. Typical DNA methylation occurs in a
CpG dinucleotide context, where predominantly CpG
sites are methylated in the genome. Most of the CpG
clusters, known as CpG islands, occur near transcrip-
tional start sites (TSSs) where they are predominantly
unmethylated. The establishment and maintenance of
methylation patterns resulting in modulation of gene ex-
pression is one of the key steps in epigenetic regulation
during normal developmental programs. The significant
overlapping between lncRNA and DNA methylation
clustering might be due to frequent methylation of CpG
clusters closed to TSSs of lncRNAs altering their land-
scape. However, we cannot discard cross-regulation be-
tween DNA methylation and specific lncRNAs, such as
has been described for H19 [32] or ecCEBPA [33] re-
cently. Interestingly, c1 contains almost all “hypomethy-




Fig. 5 LncRNA-based clustering and clinical parameters. a Kaplan-Meier plot of TCGA HNSCC patients stratified by lncRNA clusters using overall
survival as endpoint. p val was calculated with the log-rank test. n: number of patients with available follow-up information. b Significant associations
between lncRNA clusters and various clinical parameters, including tobacco, histologic grade, and sub-anatomical location. Odds ratios and significance
values were calculated using Fisher’s exact test. c Box plots of patient age for significant differences between c1 or c2 patients. p values were calculated
using T test
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(Fig. 1a), concomitant with enrichment in NSD1 inacti-
vating mutations. Similar mutations have also been
found in squamous cell carcinoma of the skin [34]. This
correlation between NSD1 mutations and the “hypo-
methylated” samples has been previously reported in the
TCGA HNSCC cohort [5, 35]. NSD1 is a histone 3 Lys
36 (H3K36) methyltransferase similar to SETD2, which
is frequently mutated in the clear cell variant of renal
cell carcinoma, and associated with DNA hypomethyla-
tion [36]. Moreover, a DNA hypomethylation signature
has been reported in Sotos syndrome, a monogenic dis-
order defined by germline NSD1 mutations [37]. Several
reports showed that H3K36 methylation is linked to the
binding of de novo DNA methyltransferases (DNMT3A
and DNMT3B) [38, 39]. Therefore, the recruitment of
DNMT3A and DNMT3B could be impaired in NSD1
mutant tumors, leading to the global DNA hypomethyla-
tion observed in the c1 cluster. Whether this DNA
hypomethylation is affecting c1 lncRNA expression
regulation warrants further investigation.
TP53 mutations have been associated with poor sur-
vival in many cancer types [40]. We believe that the ag-
gressiveness of the disease in c1 and c2 patients might
be, at least partially, explained by the increased TP53
mutation frequency. The reverse would apply for c5, al-
most depleted on mutations, and having the best overall
survival of all clusters.
In relation with other clinical parameters analyzed, the
anatomical location was the most significantly associated
with lncRNA clustering, with c1 and c2 in larynx, c4 in
tongue, or c5 in tonsil. This finding might be explained
by the already known high tissue specificity of lncRNA
expression [41] and highlights an important issue:
HNSCC as a group includes different tumor locations
and different etiologies. Therefore, we consider that
some of the surrogate lncRNAs in the clusters might be
specific for sub-anatomical locations in the head and
neck regions, and may help to analyze location-specific
associations between molecular and phenotype features.
For example, c5 overexpressed coding genes are
enriched in proteins involved in “lymphocyte activation,”
a process that occurs in the tonsils, which is an immune
defense organ in the aerodigestive tract constituting the
first line of defense against ingested or inhaled foreign
pathogens. Naturally, both B and T cell activation occurs
in the tonsils after the uptake of antigens produced by
pathogens by specialized antigen capture cells called M
cells. Whether the enrichment in “lymphocyte activa-
tion” found in c5 is due to tonsil-dependent functions or
to a specific immune response to HPV-positive tumors
remains to be ascertained.
Between the PCGs underexpressed in c1, we found
programmed death-ligand 1 (PD-L1; also called CD274).
PD-L1, which is expressed on many cancer and immune
cells, plays an important part in blocking the “cancer im-
munity cycle” by binding programmed death-1 (PD-1)
and B7.1 (CD80), both of which are negative regulators
of T-lymphocyte activation [42]. Binding of PD-L1 to its
receptors suppresses T cell migration, proliferation, and
secretion of cytotoxic mediators, and restricts tumor cell
killing. The PD-L1-PD-1 axis protects the host from
overactive T-effector cells not only in cancer but also
during microbial infections. Blocking PD-L1 should
therefore enhance anticancer immunity, and successful
Table 1 Summary of significant associations with lncRNA simple clusters
lncRNA cluster c1 c2 c3 c4 c5













lncRNAs UP 91 275 9 13 245
PCGs UP 293 792 133 389 1485
PCGs DOWN 80 132 33 104 150
Age Younger Older
Tobacco Smokers Smokers
Tumor grade ENRICHED G1, G2 G3, G4
Tumor grade DEPLETED G1 G3 G1, G2
Anatomic location ENRICHED Larynx Larynx Tongue Tonsil
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treatment of many patients with advanced cancer using
antibodies against PD-L1 has been demonstrated,
including HNSCC [43]. Thus, the Food and Drug
Administration (FDA) recently approved pembrolizu-
mab, an antibody inhibiting PD-L1, for the treatment of
some patients with recurrent or metastatic HNSCC that
has continued to progress despite standard-of-care treat-
ment with chemotherapy. However, little is known about
predictive factors of efficacy of such therapies, although
some recent reports described that across multiple can-
cer types, responses are observed in patients with tu-
mors expressing high levels of PD-L1, especially when
PD-L1 was expressed by tumor-infiltrating immune
cells. Therefore, it is tempting to speculate that c1 pri-
mary tumors would be less sensitive to anti-PD-L1 ther-
apies than the tumors from the other clusters. In
addition, some of the c1 lncRNAs might be involved in
this PD-L1-PD-1 “cancer immunity cycle” and could be
subject of future investigations.
Coding genes involved in synaptic transmission and
neuron differentiation are coexpressed with surrogate
lncRNAs within cluster c2. Perineural invasion occurs in
an important proportion of HNSCC samples. We found
no significant higher frequency of perineural invasion in
c2 samples compared with the remaining samples
(Fisher’s exact test, p val = 0.5). Therefore, it is tempting
to speculate that c2 samples might display some cellular
plasticity from epithelial towards neuroendocrine lineage,
as HNSCC tumors with neuroendocrine phenotype has
been described [44]. Recently, neuroendocrine lineage
plasticity enabled by the loss of TP53 and RB1 function
was shown in prostate cancer, mediated by increased ex-
pression of the reprogramming transcription factor SOX2
[45]. Interestingly, c2 display higher frequency of TP53
mutations (Fig. 2c and Table 1). Possibly, lncRNAs within
c2 might be involved in mechanisms regulating epithelial
to neuroendocrine reprogramming.
Many overexpressed PCGs in c5 are related to “cell
cycle” processes, suggesting that c5 carcinomas are more
proliferative. This finding is in line with the oncogenic
activities of HPV E7 oncoprotein, which binds and in-
duces protein degradation of cell cycle regulators such
as the retinoblastoma protein family, including pRb
(RB1), p107 (RBL1) or p130 (RBL2) [46]. Degradation of
these proteins, mainly pRb, allow E2F transcription fac-
tors to induce expression of genes involved in cell cycle
progression [47], such as cyclins and cyclin-dependent
kinases, or proteins involved in DNA replication, and
mitotic division. In addition, E2F1 gene amplification
was found in HPV-positive HNSCC tumors from the
TCGA cohort [5], which correlates with a molecular
profile of cell cycle deregulation. Therefore, some c5
lncRNAs might also be involved in these processes, and
possibly in the E7-pRb-E2F axis of cell cycle deregulation
of HPV-infected tumors. Tumors from c4 overexpresses
PCGs involved in epidermal differentiation, such as LCE
cluster SPRR genes, normally involved in terminal epithe-
lial differentiation. This result might be in line with the
high frequency of differentiated carcinomas in c4
(histologic grades G1 and G2) (Fig. 5 and Table 1),
whereby G3 tumors are less frequent. Therefore, some of
the c4 surrogate lncRNAs could be involved in epithelial
differentiation.
Conclusions
We present the first comprehensive clustering analysis
of HNSCC based on lncRNA expression performed to
date. The results allow selection of surrogate lncRNA
genes of five distinct tumor groups and propose possible
functions associated with them, as well as phenotypic
and clinicopathology features that may be consequence,
in part, of their activities.
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